Evolent Health Bundle
Who owns Evolent Health?
The ownership of Evolent Health shapes its strategy and potential deals, especially after late-2024 buyout rumors. Institutional investors hold concentrated voting power, influencing the company’s shift toward value-based care.
Evolent, founded in 2011 and based in Arlington, Virginia, had a market cap near $2.5 billion in early 2025; ownership mixes founders, strategic partners, and large institutions steering governance and M&A outcomes.
See related analysis: Evolent Health Porter's Five Forces Analysis
Who Founded Evolent Health?
Evolent Health's founders combined provider and advisory expertise: UPMC and The Advisory Board Company incubated the firm in 2011, led by inaugural CEO Frank Williams with Seth Blackley and Tom Peterson shaping strategy and operations.
Founding partners
UPMC and The Advisory Board Company provided the initial strategic and operational backbone for Evolent Health.
Leadership team
Frank Williams served as inaugural CEO; Seth Blackley and Tom Peterson filled key founding roles driving growth and client strategy.
Initial funding
UPMC and The Advisory Board provided $24,000,000 in seed funding to launch the platform with clinical data access and client relationships.
Ownership model
The company adopted a 'strategic-first' ownership structure where the two founders held majority control and board representation.
2013 growth round
TPG Growth invested $100,000,000 in 2013 for a significant minority stake to fund national expansion.
Governance safeguards
Founders and corporate backers implemented vesting schedules and buy-sell agreements to lock in commitment to value-based care objectives.
The early ownership structure balanced provider influence with advisory expertise, shaping Evolent Health's corporate structure and investor base and setting the stage for later public and private ownership changes; see Mission, Vision & Core Values of Evolent Health for related context.
Key early ownership facts
Foundational ownership and capitalization that defined early strategy and governance.
- Founders: UPMC and The Advisory Board Company held primary equity at inception.
- Leadership: Frank Williams (CEO), Seth Blackley, Tom Peterson led early operations.
- Seed funding: $24,000,000 provided access to clinical data and client network.
- 2013 investment: TPG Growth contributed $100,000,000 for minority ownership to accelerate expansion.
Evolent Health SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Evolent Health’s Ownership Changed Over Time?
Key events reshaping Evolent Health ownership include the June 2015 IPO that raised $195,000,000, the gradual exit of original strategic parents after UnitedHealth/Optum’s deal for The Advisory Board, and the post-2020 institutional accumulation that by 2025 places over 96% of shares with institutional investors.
| Year / Event | Ownership Impact | Notable Figures |
|---|---|---|
| June 2015 — IPO | Transition from private strategic parents to public shareholders; liquidity for founders | $195,000,000 raised |
| 2017–2020 — Advisory Board acquisition by UnitedHealth/Optum | Strategic parent stake reduced and ultimately divested | Stake exited over multiple filings |
| 2021–2025 — Institutional accumulation | Institutional investors exceed 96% of outstanding shares; professionalized cap table | Vanguard ~11.5%, BlackRock ~8.8% |
| 2024 — Magellan Specialty Health acquisition | Increased leverage and shifted investor focus to EBITDA and cash flow | Purchase price: $2,100,000,000 |
Current ownership structure of Evolent Health reflects a dominance of global asset managers; strategic operational influence moved from former parents and health systems to institutional investors who now materially shape governance and performance priorities.
Major shareholders and governance influence
By 2025 the largest holders are institutional investors, pivoting the company toward financial metrics and cash generation.
- The Vanguard Group — approximately 11.5% of shares
- BlackRock, Inc. — approximately 8.8%
- Other large positions: T. Rowe Price Associates, Neuberger Berman Group
- Institutional ownership exceeds 96%, creating one of the most professionalized cap tables in healthcare technology
For additional context on corporate strategy and investor messaging that influenced ownership shifts, see Marketing Strategy of Evolent Health
Evolent Health PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Evolent Health’s Board?
Seth Blackley serves as Chair and CEO of Evolent Health, leading a board composed of healthcare executives and financial specialists; Cheryl Scott is the Lead Independent Director. The single-class common stock structure enforces one-share-one-vote, concentrating control among the top institutional holders.
| Director | Role | Background |
|---|---|---|
| Seth Blackley | Chair & CEO | Former executive at healthcare services firms; consolidated leadership post-Frank Williams retirement |
| Cheryl Scott | Lead Independent Director | Experience with Bill and Melinda Gates Foundation and Group Health Cooperative |
| Independent Directors (collective) | Board Members | Mix of healthcare veterans and financial experts to support M&A and governance |
The board’s composition and governance reflect the company’s ownership dynamics: with a single-class common stock, voting power aligns with equity stakes, and the top ten institutional shareholders effectively shape strategic outcomes and potential M&A activity.
Board control and activist influence
Institutional concentration and activist stakes have driven board changes and a sharper focus on shareholder returns by 2025.
- One-share-one-vote common stock: voting mirrors ownership percentages
- Top 10 institutional holders hold a determinative block of votes in practice
- Engaged Capital and similar activists pressed for operational fixes and strategic alternatives
- Board optimized for complex M&A scenarios; acquisition interest from managed care and private equity heightened
As of 2025 filings, institutional investors such as Vanguard, BlackRock and State Street remain among the largest shareholders by percentage, collectively representing roughly 20–30% of outstanding shares; activist positions have historically ranged from 5–10%, influencing board nominations and strategic reviews — see further context in Growth Strategy of Evolent Health
Evolent Health Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Evolent Health’s Ownership Landscape?
In the past three years Evolent Health ownership has shifted toward consolidation and institutional scale investors, driven by the 2023 Magellan Specialty Health acquisition and rising event-driven interest amid take-private rumors.
| Year | Ownership Trend | Key Data |
|---|---|---|
| 2023 | Acquisition-driven dilution and new strategic investors | Magellan Specialty Health acquisition; material shareholder mix change |
| 2024 | Increase in event-driven and activist stakes | Rumors of take-private deals; greater hedge fund interest |
| 2025 | Institutional scale attraction; lower insider ownership | Targeting annual revenues ~$2.6 billion; insider ownership 3% |
Public filings and 2025 analyst commentary show management pursuing the standalone 'Evolent Blueprint' while remaining open to ownership transactions that enhance institutional value; passive ETF flows have also raised sensitivity to sector volatility.
Ownership concentration
Top institutional holders and event-driven funds grew in representation between 2023–2025, increasing the stock's susceptibility to block trades and takeover approaches.
Insider dilution
Founder and executive stakes declined to below 3% by 2025 as earlier shareholders diversified after a decade of growth.
Revenue scale impact
Projected ~$2.6 billion annual revenue in 2025 positions the company for more institutional interest tied to the Value-Based Care 2.0 narrative.
Market mechanics
Rising passive ETF ownership links stock performance to broader healthcare sector moves, affecting Evolent Health ownership stability and takeover dynamics.
Refer to the Brief History of Evolent Health for background on the company’s acquisition history and corporate structure.
Evolent Health Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of Evolent Health Company?
- What is Competitive Landscape of Evolent Health Company?
- What is Growth Strategy and Future Prospects of Evolent Health Company?
- How Does Evolent Health Company Work?
- What is Sales and Marketing Strategy of Evolent Health Company?
- What are Mission Vision & Core Values of Evolent Health Company?
- What is Customer Demographics and Target Market of Evolent Health Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.